Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-59P (RNA, U4 small nuclear 59, pseudogene) represents a pseudogene related to the U4 small nuclear RNA gene family. Pseudogenes are DNA sequences similar to normal genes but are non-functional; they may arise from gene duplication or retrotransposition events and typically do not produce functional RNA or protein products. No evidence supports a role for RNU4-59P as an active, functional RNA or as a direct participant in any biological process, human disease, or therapeutic targeting. It is not considered a therapeutic target and has no known biological, clinical, or pharmacological relevance. The suffix "P" in RNU4-59P designates it as a pseudogene, and there is no primary literature or database reference to RNU4-59P being expressed, functional, or associated with clinical conditions. Most public repositories, including gene databases and the provided search results, list only the functional U4 snRNA genes or discuss pseudogenes generically. No evidence of pharmacologic intervention, disease link, or biomarker status for RNU4-59P exists in recent genome or transcriptome studies. As a non-functional pseudogene, not an active RNA or protein, RNU4-59P cannot serve as a therapeutic target, biomarker, or be associated with direct biological or disease roles. Its inclusion in target lists constitutes a data curation or annotation error, likely due to confusion with the functional homolog RNU4-2. Therefore, if searching for active spliceosomal snRNAs, focus on RNU4-2 or similar functional genes. RNU4-59P should not be used as a molecular or therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 59, pseudogene (RNU4-59P).